{
  "source": "PA-Med-Nec-Winrevair.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2343-2\nProgram Prior Authorization/Medical Necessity\nMedication Winrevair™ (sotatercept-csrk)\nP&T Approval Date 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nWinrevair (sotatercept-csrk) is an activin signaling inhibitor indicated for the treatment of adults\nwith pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity,\nimprove WHO functional class (FC) and reduce the risk of clinical worsening events.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Winrevair will be approved based on all of the following criteria:\na. One of the following:\n(1) All of the following:\n(a) Diagnosis of pulmonary arterial hypertension (PAH)\n-AND-\n(b) PAH has been confirmed by right heart catheterization\n-AND-\n(c) Prescriber attestation that other types of pulmonary hypertension (PH) are\nexcluded as a diagnosis\n-AND-\n(d) Pulmonary arterial hypertension is symptomatic\n-OR-\n(2) Both of the following:\n(a) Diagnosis of pulmonary arterial hypertension\n-AND-\n(b) Patient is currently on Winrevair therapy as documented by claims history\nor submission of medical records (document date and duration of therapy)\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\nb. One of the following:\n(1) Both of the following:\n(a) Patient has a cardiopulmonary comorbidity (e.g., obesity, hypertension,\ndiabetes mellitus, coronary heart disease)\n-AND-\n(b) Patient is currently taking at least one of the following oral therapies:\ni. Endothelin receptor antagonist (ERA) [e.g., ambrisentan, bosentan,\nOpsumit (macitentan)]\nii. Phosphodiesterase-5 inhibitor (PDE5i) (e.g., sildenafil, tadalafil)\n-OR-\n(2) Both of the following:\n(a) Patient does not have a cardiopulmonary comorbidity (e.g., obesity,\nhypertension, diabetes mellitus, coronary heart disease)\n-AND-\n(b) Patient is currently taking oral combination therapy with both of the\nfollowing:\ni. Endothelin receptor antagonist (ERA) [e.g., ambrisentan, bosentan,\nOpsumi",
    "ellitus, coronary heart disease)\n-AND-\n(b) Patient is currently taking oral combination therapy with both of the\nfollowing:\ni. Endothelin receptor antagonist (ERA) [e.g., ambrisentan, bosentan,\nOpsumit (macitentan)]\nii. One of the following:\n• Phosphodiesterase-5 inhibitor (PDE5i) (e.g., sildenafil, tadalafil)\n• Soluble guanylate cyclase stimulator (sGC) [e.g., Adempas\n(riociguat)]\n-AND-\nc. Prescribed by, or in consultation with, a cardiologist, pulmonologist, or\nrheumatologist\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Winrevair will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Documentation of a positive clinical response to Winrevair therapy [e.g.,\nimprovement in symptoms of right heart failure, exercise tolerance, six-minute\nwalk distance (6MWD), resting and ambulatory oximetry]\n-AND-\nb. Prescribed by, or in consultation with, a cardiologist, pulmonologist, or\nrheumatologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limitations may be in place.\n4. References:\n1. Winrevair [package insert]. Rahway, NJ: Merck & Co., Inc; March 2024.\n2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis\nand treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.\nProgram Prior Authorization/Medical Necessity – Winrevair™ (sotatercept-csrk)\nChange Control\n6/2024 New program.\n6/2025 Annual review. No changes to coverage criteria\n© 2025 UnitedHealt",
    "2022; 43:3618.\nProgram Prior Authorization/Medical Necessity – Winrevair™ (sotatercept-csrk)\nChange Control\n6/2024 New program.\n6/2025 Annual review. No changes to coverage criteria\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}